Protocol and operational feasibility
Assess protocol fit, investigator experience, patient populations, facilities, competing studies, and enrollment assumptions before recommending sites.
Home
Sponsors & CROs
Site selection, activation, and execution—coordinated around your protocol.
ClinRé gives sponsors and CROs coordinated access to qualified investigators, research-ready sites, and diverse patient communities—from operational feasibility and site selection through activation, recruitment, quality oversight, and closeout.
Evaluate a protocolThe ClinRé model
Central coordination without losing local accountability.
Every protocol has different scientific, operational, geographic, and enrollment requirements. ClinRé evaluates fit at the investigator and site level, then coordinates the work needed to move appropriate sites toward activation and execution.
Our role is not to replace the sponsor, CRO, principal investigator, or site team. It is to help those parties work together through a clearer and more consistent operating structure.
From feasibility to closeout
Six connected capabilities.
Site identification and selection
Match each protocol with qualified investigators and research-ready sites using therapeutic, geographic, and operational criteria.
Site activation and start-up
Coordinate confidentiality agreements, budgets, contracts, regulatory documents, training, and activation-readiness activities.
Multi-site study execution
Apply centralized coordination, standardized workflows, and clear escalation pathways while preserving principal-investigator and site accountability.
Patient recruitment and retention
Translate local patient access, referral relationships, and community pathways into protocol-specific recruitment and retention plans.
Quality oversight and inspection readiness
Support protocol compliance, documentation and data quality, issue escalation, training oversight, and audit and inspection readiness.
Our experience
Selected Sponsors and Research Partners
Organizations represented across ClinRé’s clinical-trial, research, healthcare, and operating relationships.
Sponsors and Medical-Technology Companies
AbbottAkura MedicalAstraZenecaAvantecAveeraAVSBDCVRxW. L. Gore & AssociatesJazz PharmaceuticalsKardionMedAllianceMedtronicMicro MedicalOrchestra BioMedPenumbraPfizerPhilipsREVASanofiShockwave MedicalTerumo
Clinical and Research Partners
Advanced Heart and Vein CenterCareLifeDuke MedicineLoudoun Heart and VascularMedStar HealthMercy HealthPremier Cancer Care and Infusion CenterScience 37Tarrant Neurology ConsultantsThe CNSWashington Vascular Specialists
Technology and Operating Partners
Vianova
Study phases
Routine late-phase execution, with Phase I capability ahead.
ClinRé regularly supports Phase II through Phase IV clinical trials. Phase I capability is scheduled to open in the first quarter of 2027 across Texas, California, Missouri, and Virginia.
Established network support for Phase II, Phase III, and Phase IV sponsor and CRO relationships.
Planned Phase I access in Texas, California, Missouri, and Virginia.
Designed to improve study execution
ClinRé’s coordinated site-network model is designed to support:
- Faster, more informed feasibility responses
- Appropriate investigator and site selection
- Reduced variability during start-up
- Clearer sponsor, CRO, and site communication
- Recruitment strategies grounded in local patient pathways
- Consistent operational reporting and issue escalation
- Quality-focused execution through closeout
What to bring us
Start with the protocol—not a generic site count.
Therapeutic and operational needsIndication, phase or device pathway, study design, key inclusion criteria, and site requirements.
Target geographiesPreferred markets, site volume, launch sequence, and any population diversity priorities.
Timelines and constraintsFeasibility deadlines, activation targets, recruitment window, and study-specific dependencies.
Engagement modelWhat the sponsor or CRO wants ClinRé to coordinate centrally and what remains directly managed.
Study opportunities